The discoveries of the BRCA1 and BRCA2 genes have made it possible for women of families with hereditary breast/ovarian cancer to determine if they carry cancer-predisposing genetic mutations. Women with germline mutations have significantly higher probabilities of developing both cancers than the general population. Since the presence of a BRCA1 or BRCA2 mutation does not guarantee future cancer development, the appropriate course of action remains uncertain for these women. Prophylactic mastectomy and oophorectomy remain controversial since the underlying premise for surgical intervention is based more upon reduction in the estimated risk of cancer than on actual evidence of clinical benefit. Issues that are incorporated in a woman\u27s d...
Objective. Risk-reducing surgery is advised to BRCA1/2 pathogenic variant (PV) carriers around the a...
Background. Little is known about the factors that women at increased risk of ovarian cancer conside...
Objective. Risk-reducing surgery is advised to BRCA1/2 pathogenic variant (PV) carriers around the a...
The discoveries of the BRCA1 and BRCA2 genes have made it possible for women of families with heredi...
With technological advances in testing for gene mutations, a new population of BRCA1/2 women is beco...
With technological advances in testing for gene mutations, a new population of BRCA1/2 women is beco...
Women found to carry mutations in the BRCA1 or BRCA2 genes have up to an 88% lifetime risk of breast...
Women with a suspected BRCA1/2-mutation may choose between two management options: breast cancer scr...
Women found to carry mutations in the BRCA1 or BRCA2 genes have up to an 88% lifetime risk of breast...
Women who have a breast cancer genetic mutation (BRCA) are at a significantly increased risk for the...
Women who have a breast cancer genetic mutation (BRCA) are at a significantly increased risk for the...
With technological advances in testing for gene mutations, a new population of BRCA1/2 women is beco...
Women with a BRCA1/2 genetic mutation have an increased risk of developing breast and ovariumcancer....
Women with BRCA1 or BRCA2 mutations are at increased risk of developing breast and ovarian cancer. O...
Women with BRCA1 or BRCA2 mutations are at increased risk of developing breast and ovarian cancer. O...
Objective. Risk-reducing surgery is advised to BRCA1/2 pathogenic variant (PV) carriers around the a...
Background. Little is known about the factors that women at increased risk of ovarian cancer conside...
Objective. Risk-reducing surgery is advised to BRCA1/2 pathogenic variant (PV) carriers around the a...
The discoveries of the BRCA1 and BRCA2 genes have made it possible for women of families with heredi...
With technological advances in testing for gene mutations, a new population of BRCA1/2 women is beco...
With technological advances in testing for gene mutations, a new population of BRCA1/2 women is beco...
Women found to carry mutations in the BRCA1 or BRCA2 genes have up to an 88% lifetime risk of breast...
Women with a suspected BRCA1/2-mutation may choose between two management options: breast cancer scr...
Women found to carry mutations in the BRCA1 or BRCA2 genes have up to an 88% lifetime risk of breast...
Women who have a breast cancer genetic mutation (BRCA) are at a significantly increased risk for the...
Women who have a breast cancer genetic mutation (BRCA) are at a significantly increased risk for the...
With technological advances in testing for gene mutations, a new population of BRCA1/2 women is beco...
Women with a BRCA1/2 genetic mutation have an increased risk of developing breast and ovariumcancer....
Women with BRCA1 or BRCA2 mutations are at increased risk of developing breast and ovarian cancer. O...
Women with BRCA1 or BRCA2 mutations are at increased risk of developing breast and ovarian cancer. O...
Objective. Risk-reducing surgery is advised to BRCA1/2 pathogenic variant (PV) carriers around the a...
Background. Little is known about the factors that women at increased risk of ovarian cancer conside...
Objective. Risk-reducing surgery is advised to BRCA1/2 pathogenic variant (PV) carriers around the a...